Sector: MedicalVertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
Headlines
- RidgewaterEquity.com Free Fundamental Sector & Market Research on FLEX, ISIL, VRTX, JNPR, COCO and EBAY
Nov 05, 2009 05:29 AM | EBAY, FLEX, ISIL, JNPR, VRTX
- Gloomy Put Options Posturing On Financials ETF
Nov 02, 2009 04:53 PM | BEBE, CF, ETFC, F, HGSI, LDK
- Innovative Drug Companies Headline The Gainers
Nov 02, 2009 04:49 PM | AMLN, HGSI, VRTX
- Dr. Stockpick Announces Daily Stock Watch - AMLN, VRTX, HGSI
Nov 02, 2009 09:40 AM | AMLN, HGSI, VRTX
- More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens
Oct 31, 2009 05:30 PM | VRTX
- Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences
Oct 30, 2009 04:57 PM | VRTX
- Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment
Oct 28, 2009 07:00 AM | VRTX
- Vertex Pharmaceuticals Reports Third Quarter 2009 Financial Results and Highlights Recent Business and Clinical Progress
Oct 26, 2009 04:01 PM | VRTX
- Vertex Pharmaceuticals Announces the Date of its Third Quarter 2009 Financial Results Conference Call and Webcast
Oct 14, 2009 04:15 PM | VRTX
- Vertex Strapped For Cash (NASDAQ: VRTX)
Oct 01, 2009 01:37 PM | VRTX
- Earnings roundup: Heartland Financial, Masco
Oct 26, 2009 06:52 PM | MAS, VRTX, WCBO
- Movers: Home Depot, Wellcare, Lehman Brothers, Target
Aug 20, 2008 10:51 AM | CME, FII, GD, HD, LEH, MDT
- Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Adams Global Growth Conference
Aug 06, 2009 04:42 PM | VRTX
- BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
Aug 06, 2009 06:53 AM | ARNA, AVII, AZN, BMR, CEPH, EPCT
- Vertex Pharmaceuticals Reports Second Quarter 2009 Financial Results and Highlights Recent Clinical Progress and Business Development Activity
Aug 05, 2009 04:13 PM | VRTX
- Vertex Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation Amend Agreement to Develop and Commercialize Telaprevir in Asia
Jul 30, 2009 03:38 AM | VRTX
- Vertex Pharmaceuticals Announces the Date of its Second Quarter 2009 Financial Results Conference Call and Webcast
Jul 27, 2009 04:17 PM | VRTX
- Third Rock Ventures Expands Team With Biotech Veterans
Jul 21, 2009 10:02 AM | CBST, ILI, VRTX
- BenchmarkJournal.Com Free Analyst Review for SWHC, AMAT, SYNA, VRTX, CPHD and AKAM
Jul 13, 2009 10:19 AM | AKAM, AMAT, CPHD, SWHC, SYNA, VRTX
- Vertex Pharmaceuticals Announces Intention to Sell Its Rights to European Milestone Payments for Telaprevir
Jul 10, 2009 05:36 AM | VRTX
- Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals’ Board of Directors
Jul 07, 2009 04:33 PM | VRTX
- Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2009 Piper Jaffray Europe Conference
Jun 23, 2009 09:47 AM | VRTX
- Form 4 BOGER JOSHUA S For: Oct 27 (10K)
Nov 05, 2009 04:04 PM
- Form 4 VERTEX PHARMACEUTICALS For: Oct 22 Filed by: SMITH IAN F (10K)
Oct 26, 2009 06:20 PM
- Form 4 VERTEX PHARMACEUTICALS For: Oct 22 Filed by: Sachdev Amit (10K)
Oct 26, 2009 06:18 PM
- Form 4 VERTEX PHARMACEUTICALS For: Oct 22 Filed by: MUELLER PETER (10K)
Oct 26, 2009 06:16 PM
- Form 4 VERTEX PHARMACEUTICALS For: Oct 22 Filed by: Kelly Lisa (10K)
Oct 26, 2009 06:15 PM
- Form 4 VERTEX PHARMACEUTICALS For: Oct 22 Filed by: BOGER KENNETH S (10K)
Oct 26, 2009 06:13 PM
- Form 4 VERTEX PHARMACEUTICALS For: Oct 21 Filed by: BOGER JOSHUA S (10K)
Oct 22, 2009 03:32 PM
- Form 4 VERTEX PHARMACEUTICALS For: Oct 19 Filed by: Graves Kurt (10K)
Oct 21, 2009 03:35 PM
- Form 4 BOGER JOSHUA S For: Oct 14 (10K)
Oct 15, 2009 05:26 PM
- Form 4 BOGER JOSHUA S For: Oct 07 (10K)
Oct 08, 2009 03:44 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
VRTX
|
Compare to S&P
|
| YTD |
10.47 %
|
-3.71 %
|
| 4 Weeks |
-4.09 %
|
-5.10 %
|
| 12 Weeks |
-3.67 %
|
-6.06 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 9.78 %
|
|
EPS Growth in Last Year: 10.75 %
|
|
Sales Growth in Last Quarter: 30.91 %
|
|
Sales Growth in Last Quarter: -21.04 %
|
|
